Bora Pharmaceuticals Co Ltd · TWSE:6472
Bora Pharmaceuticals — Q3 2023 Earnings Presentation
21 slides from Bora Pharmaceuticals's earnings presentation, November 2023
Slide 1: Third Quarter 2023 Results
THIRD QUARTER 2023 RESULTS November 2023
Slide 2: Agenda
Agenda Recent Development & Operational Updates Financial Highlights 2023 Strategic Deliverables & YTD Progress Q&A
Slide 3: Q3'23 Operational Updates
Q3’23 Operational Updates
Slide 4: Dual-line growth in Global CDMO & Commercial Business
Dual-line growth in Global CDMO & Commercial Business Robust Business Growth • Q3’23 consolidated revenue reached NT$3.08 billion, 13% YoY growth Global CDMO • 42% of total revenue YoY QoQ + 11 new molecules – 9 small molecules (including one ophthalmic product) and 2 biologics 19% 12% + 6 new custo
Slide 5: Global CDMO – Strengthening New Business Development Platform
Global CDMO – Strengthening New Business Development Platform 2023 first three quarter Including Small Molecule +24 New Products • 50% compared to the same +3 US Market Ophthalmic Products • 2 projects contracted with ONE global well-known customer period in 2022 • Launched TWI new products • CPhI B
Slide 6: Global commercial – Growing product portfolio and market reach
Global commercial – Growing product portfolio and market reach 1. Dicyclomine HCL Tablet 2 Product Launch • 3rd successful TWi product manufactured by Zhunan site US 2. FORFIVO XL Market & • Launched the largest brand, Forfivo, through TWI US Channel in Sep 2023 Successful Portfolio Expansion 3. Ent
Slide 7: Another Strategic Move for More Synergies
Another Strategic Move for More Synergies
Slide 8: SunWay Biotech
SunWay Biotech - Pioneer in Microbiology and Fermentation Technology Approximate Capital NTD R&D staff Health, the ratio R&D budget for 2022 R&D Vision carefree way 3.4B 36% 12% 30+ PMP NPDP RD PL Professional Health Food Professional Health Food We apply diverse Project Management New Product Devel
Slide 9: SunWay Biotech Unique Core Competence to Win Global Nutraceuticals Market
SunWay Biotech Unique Core Competence to Win Global Nutraceuticals Market Diverse Microorganisms ~ Top leading brands 1 % of Probiotic/Lactic acid % of Red yeast rice Market bacteria market Share in Share in Taiwan Taiwan 1.22 0.93 1.39 0.93 1.17 SunWay’s Proprietary Strains 4.34 1.91 2.6 4.21 1.64
Slide 10: SunWay Biotech Well-positioned for Global Expansion
SunWay Biotech Well-positioned for Global Expansion Acquire Italian food supplement certification Corporation with European branded company Our company established Chentai Biotechnology in the Acquire certification, second half of 2017 in cooperation with local Songshan Lake, Dongguan, brand company
Slide 11: Certificates and Standards Recognized by International Authorities
SunWay Biotech Certificates and Standards Recognized by International Authorities Canada Italy MOH NPN #80071270 Food supplement #87750 Copyright ® SunWay Biotech Co., LTD. NDI (#1071) Assisting USP in the Malaysia development of dietary MAL and HALAL certification Singapore New Dietary Ingredient M
Slide 12: International Features – SCI Journal Cover Story & Awards
SunWay Biotech International Features – SCI Journal Cover Story & Awards Winner of NUTRA Ingredients Asia Copyright ® SunWay Biotech Co., LTD. Awards 2023 Microbiological Research and Development Featured as the Cover Story in the Food & Function Journal 12
Slide 13: Patents in Major Markets Globally
SunWay Biotech Patents in Major Markets Globally Title Patent Composition and method for prevention and treatment of Alzheimer’s Taiwan (2013.09), Taiwan (2011.05) Disease Composition for lowering blood lipid and elevating high density Taiwan (2013.11), China (2016.05), Japan (2016.04), Canada lipop
Slide 14: More Synergies to be Realized for Global Nutraceutical Market
More Synergies to be Realized for Global Nutraceutical Market Strategic Alliance A leading nutraceutical developer in A global development and distribution Taiwan established as a centre of via Share Swap partner of pharmaceuticals and health excellence for the R&D of health food and ingredients foo
Slide 15: Q3'23 Financial Highlights
* Better Health All bo [(@ Over the World Q3'23 Financial Highlights
Slide 16: Strong Growth Momentum by “Dual-Engine” Strategies
Strong Growth Momentum by “Dual-Engine” Strategies Growth Engine for Q3’23 Revenue Composition for Q3’23 Q3’23 = Commercial Sales NT$3,075mn 58% CDMO 42% Q3’22 = NT$2,724mn US TW, 8% Others, 13% TST, 1% MGA, 1% SFT, 2% KCL, 5% DLS, 62% DTC, 7% 16
Slide 17: Q3'23 Financials Financial Highlights
Q3’23 Financials Financial Highlights Key Financials YoY QoQ (in NTD millions, except for EPS) Q3'23 Q3'22 % Q2'23 % • Revenue breakdown: 42% Revenue 3,075 2,724 13% 3,139 -2% CDMO vs 58% Commercial COGS (1,431) (1,822) (1,414) Gross Profits 1,644 902 82% 1,724 -5% • Q3’22 – TWi was GM % 53% 33% 55%
Slide 18: Another Record Year Expected with Outperforming 9M'23 Results
Another Record Year Expected with Outperforming 9M’23 Results Revenue (NT$’mn) Gross Profits (NT$’mn) 10,994 5,294 10,494 2,913 1,672 4,900 704 1,800 2020 2021 2022 9M'23 GM (%) 39% 34% 28% 48% 2020 2021 2022 9M'23 Operating Income (NT$’mn) Net Profits (NT$’mn) 4,113 2,489 1,922 1,402 1,046 578 750
Slide 19: Strategic Deliverables & YTD Progress
Strategic Deliverables & YTD Progress
Slide 20: Setting the Stage for Accelerated Growth in 2024
Setting the Stage for Accelerated Growth in 2024 Global Optimize product portfolio and Global CDMO Commercial Sales continue to lift profitability • CDMO commercial launch– Celltrion and other Further expansion Continued Efficient execution global customers investment in and integration of by capita
Slide 21: Bora Group as the Leading Taiwan-based Pharma
Largest CDMO pharma company in Taiwan with well-established infrastructure Duel-engine growth strategy covering the major fast-growing segments in global pharma industry with competitive edge Superior execution of delivering the M&A synergies to maximize shareholders’ value State-of-the-art manufact